Valax D

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valax D

Quick Facts

Property Description
Active ingredients Valsartan, Hydrochlorothiazide (HCTZ)
Form Tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB) and Thiazide Diuretic Combination
General Purpose Management of high blood pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Valax D?

Valax D is a synthetic, fixed-dose combination (FDC) medicine prescribed primarily for managing high blood pressure, supplied as an oral tablet. This product is classified as an Angiotensin II Receptor Blocker (ARB) and Thiazide Diuretic Combination. This FDC is clinically recognized for providing a comprehensive blood pressure-lowering effect, often recommended when a single antihypertensive agent does not achieve optimal results. This means the combination provides a more efficient mechanism for controlling persistent hypertension in adult patients.

Active Ingredients and General Purpose

Valax D contains two active ingredients: Valsartan, the Angiotensin II Receptor Blocker, and Hydrochlorothiazide (HCTZ), the Thiazide Diuretic. This dual composition ensures the medicine targets high blood pressure through two distinct, complementary physiological actions. Valsartan helps to facilitate the widening and relaxation of blood vessels, while Hydrochlorothiazide, a sulfonamide derivative, encourages the kidneys to excrete excess water and sodium from the body. The general purpose of this specific pairing is to achieve a stable and powerful reduction in high blood pressure (hypertension), which is critical for mitigating the long-term risk of cardiovascular complications.

What side effects are possible with Valax D?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse reactions and regulatory safety constraints for the Valsartan/Hydrochlorothiazide combination, as categorized by government health authorities. This profile distinguishes between frequent, less severe effects and serious, clinically significant risks.


Regulatory Classification of Adverse Reactions

Classification Examples of Officially Documented Effects
Common (ge 1%) Dizziness, headache, fatigue, nasopharyngitis, upper respiratory tract infection.
Uncommon (<1%) Hypotension, vertigo, cough, abdominal pain, arthralgia, back pain, muscle pain.

Adverse reactions are grouped into System-Organ Classes (SOCs), affecting areas such as the Nervous System, Gastrointestinal System, Musculoskeletal System, and resulting in Metabolism and Nutrition Disorders.


Serious Safety Considerations

Regulatory documents highlight risks that, while sometimes rare, are clinically critical:

  • Angioedema: A serious hypersensitivity reaction involving swelling of the face, lips, tongue, or throat.
  • Acute Ocular Effects: The Hydrochlorothiazide (HCTZ) component has been associated with acute transient myopia and secondary angle-closure glaucoma, which typically occur within hours to weeks of drug initiation.
  • Fetal Toxicity: The medicine is explicitly contraindicated in pregnancy due to the risk of fetal and neonatal injury and death, particularly in the second and third trimesters.
  • Metabolic Imbalances: The HCTZ component can cause severe electrolyte changes, including hypokalemia (low potassium) and hyponatremia (low sodium), and may be associated with hyperuricemia (gout risk).

Safety Constraints for Specific Populations

Use is officially contraindicated in patients with severe hepatic impairment (including biliary cirrhosis or cholestasis) and patients with anuria (no urine production). Caution is also advised regarding the potential for acute renal failure or activation of Systemic Lupus Erythematosus (SLE).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Valax D (Valsartan/Hydrochlorothiazide) is officially documented to result primarily from the maximum, exaggerated effects of its two components: profound hypotension (severely low blood pressure) and severe fluid and electrolyte disturbances.

Documented Manifestations and Severe Outcomes

The most common signs of overdose are those linked to severe fluid loss, including dizziness, fainting, drowsiness, confusion, and muscle cramps. Life-threatening manifestations, as noted in official prescribing information, include circulatory collapse, seizures, and coma (unresponsiveness). The Hydrochlorothiazide component carries the specific risk of critical electrolyte shifts, such as severe hyponatremia or hypokalemia, which can lead to serious cardiac rhythm problems. Potential acute renal failure is a recognized complication of profound hypotension.

Emergency Action Required

Immediate medical attention is mandated for any suspected overdose. Emergency services must be contacted immediately if the affected individual has collapsed, experienced a seizure, has difficulty breathing, or cannot be awakened.

Management is defined as symptomatic and supportive, as no specific antidote is known. Official procedures require continuous hospital monitoring of vital signs, along with laboratory assessment of renal function and electrolyte status. This care may include the use of intravenous fluids to address severe volume depletion.

Therapeutic Uses of Valax D

Quick Facts

  • Assists in the long-term management of high blood pressure.
  • Used when blood pressure is not adequately supported by a single medication.

Valax D is a compound formulated to assist with the management of high blood pressure (hypertension). High blood pressure is a common condition that, if unaddressed, may contribute to the risk of serious events affecting the cardiovascular system, such as stroke or myocardial infarction. Therapeutic use of Valax D is aimed at supporting a reduction in elevated blood pressure.

This medication is typically reserved for instances where the patient’s blood pressure is not sufficiently controlled with a single agent (monotherapy). The therapeutic benefit of supporting a blood pressure reduction is to assist in lowering the overall cardiovascular burden on the body and potentially contribute to a reduction in certain related risks.

Patients should follow the guidance of a healthcare professional when using this medication as part of a comprehensive cardiovascular risk management plan.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Valax D?

Population eligibility for Valax D (Valsartan/Hydrochlorothiazide) is strictly defined by regulatory authorities and is restricted to adult patients with hypertension. The safety and efficacy of this combination product have not been established in children and adolescents under 18 years of age, and its use in this population is not recommended.

Official regulatory labeling establishes several absolute contraindications where use is strictly prohibited:

  • Pregnancy: Valax D is contraindicated in women who are pregnant, particularly during the second and third trimesters, as it carries a Boxed Warning regarding the risk of fetal injury and death.
  • Anuria: The medicine is contraindicated in patients with anuria (inability to produce urine) due to the Hydrochlorothiazide component.
  • Allergy: It is contraindicated for patients with hypersensitivity to any component of the product or to other sulfonamide-derived drugs.
  • Dual RAAS Blockade: The product is contraindicated for diabetic patients also taking aliskiren.

Use requires special caution or is not recommended in several specific populations. This includes patients with severe renal impairment (creatinine clearance leq 30 mL/min), severe hepatic impairment, or those who are volume- or salt-depleted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information outlines specific interaction patterns for Valax D (Valsartan/Hydrochlorothiazide) that primarily involve pharmacodynamic reinforcement and altered drug exposure.


Contraindicated Combination

Co-administration with Aliskiren is contraindicated in patients with Type 2 Diabetes Mellitus or moderate to severe renal impairment (GFR less than 60 mL/min/1.73 m^2). This restriction is due to an increased risk of adverse outcomes, including hyperkalemia and worsening renal function.

Pharmacodynamic Interactions

Combining Valax D with other antihypertensive agents or alcohol may result in an additive hypotensive effect.

  • Potassium-sparing diuretics and potassium supplements increase the risk of hyperkalemia due to the Valsartan component.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may officially reduce the antihypertensive effect and increase the risk of impaired kidney function.
  • The Hydrochlorothiazide component may reduce the renal clearance of lithium, leading to an increased risk of lithium toxicity.

Exposure and Timing Constraints

Valsartan systemic exposure may increase when co-administered with inhibitors of hepatic uptake transporters, such as OATP1B1 and OATP1B3 (e.g., Rifampin or Ciclosporin).

Separation of administration is mandatory for certain substances: Hydrochlorothiazide absorption is impaired by the bile acid sequestrants Colestyramine and Colestipol. Therefore, Hydrochlorothiazide must be administered at least 4 hours before or 4 to 6 hours after these agents.

Mechanism of Action

Valax D is an agent designed to modulate specific, dysregulated physiological signaling via targeted interventions across key biological pathways.

Primary Receptor and Target Modulation

Valax D works by acting directly on defined receptor systems, such as specific G-protein-coupled receptors (GPCRs) or ion channels, often located in central or peripheral pathways. This initial targeted binding initiates a change in the cell's responsiveness to its natural messengers, thus modifying the beginning of a signaling sequence. This mechanistic domain involves the adjustment of existing communication lines within the biological system.

Modulating Downstream Signaling Cascades

Beyond initial binding, Valax D influences the subsequent signal transduction cascades inside the cell. It modifies early molecular steps, such as the activity of second messengers or associated protein kinases. By regulating these internal processes, Valax D modulates overactive or underactive physiological responses by altering how the cell processes information.

Systemic Homeostatic Adjustment

Valax D's molecular effects influence the regulation of complex regulatory dynamics across affected biological systems. The agent engages mechanisms that influence feedback within pathways, which is relevant in systems where excessive mediators dominate. This action modifies the activity of overactive physiological responses and contributes to a more homeostatic state within the targeted pathways.

Dosage and Administration Information

How to Use Valax D: Administration Guidelines

Valax D (Valsartan/Hydrochlorothiazide) is a fixed-dose combination medication for hypertension, and its administration is governed by the prescribing information, which details the standard procedural use.


Administration Scope and Dosing

Feature Instruction
Route of Administration The fixed-dose combination product is for oral use only.
Standard Dosing Schedule The usual starting dose for add-on therapy is 160 mg / 12.5 mg (Valsartan/HCTZ) taken once daily.
Maximum Daily Dose The dosage can be increased over time up to a maximum recommended daily dose of 320 mg / 25 mg.
Titration Interval The dose may be increased after 1 to 2 weeks of therapy, if necessary, based on monitoring.

Contextual Intake and Adjustments

Valax D tablets are designed to be swallowed whole with water, and they may be administered with or without food. This flexibility simplifies the timing of the daily dose.

If a dose is missed, the instruction is to skip the missed dose and continue with the next regularly scheduled dose; the subsequent dose must not be doubled.

For specific populations, no initial dosage adjustment is required for older adults. However, use is not recommended in patients with severe renal impairment (Creatinine Clearance <30 mL/min), and use is not established or recommended in the pediatric population. These explicit instructions define the boundaries for standardized use.

Recent Clinical Evidence

Research evidence / Overview of studies for Valax D

This overview summarizes the key types of research that have been conducted to evaluate Valax D (Valsartan and Hydrochlorothiazide) and highlights what the current evidence base suggests, according to official regulatory and scientific sources. The findings described relate to group patterns observed in studies and research does not determine whether an individual will respond similarly.


Evidence for Use in Managing Essential Hypertension

Clinical evaluation for Valax D in adult patients with high blood pressure has primarily relied on randomized controlled trials (RCTs), supplemented by systematic reviews and meta-analyses. These short-term and intermediate-term studies are designed to compare the medicine against either a placebo or against the individual active components used alone.

The main focus of these studies has been to monitor and record measurements of blood pressure, specifically Mean Sitting Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), over defined time intervals. In the observed populations, studies reported patterns where the combination of ingredients was associated with differing magnitude of changes in SBP and DBP compared to when either component was used alone. These findings describe patterns observed in the studies, which also tracked the rate at which study participants met specific blood pressure goals defined within the research protocol.

While these findings help contextualize the research on blood pressure measures, they do not establish long-term evidence related to definitive clinical outcomes, such as occurrence of stroke or heart attack, specifically for the fixed-dose combination over many years. This type of research contributes to the broader evidence landscape but is not sufficient for drawing conclusions on long-term event reduction.


Evidence for Use When One Medication Is Insufficient (Step-Up Therapy)

Research examined patient populations whose high blood pressure was not adequately controlled by taking a single medication (monotherapy). These RCTs specifically compared switching a patient to the fixed-dose combination against continuing the patient on the single agent, in research exploring short-term symptom changes.

The research monitored the change in SBP and DBP recorded by introducing the second active ingredient. Studies consistently monitored the rate at which patients achieved blood pressure targets following the change. Research indicates that in observed populations whose symptoms remained unstable on monotherapy, changes in blood pressure measurements were recorded after transitioning to the combination. This research helps show what has been observed so far regarding the incremental effect of using the two ingredients together.


Long-Term Studies and Follow-Up Data

Studies focusing on the immediate effect of Valax D combination typically had follow-up durations that were limited, often lasting only 4 to 12 weeks for primary efficacy assessments. Some trials extended to 26 weeks, but sustained, long-term observation remains insufficient for the specific fixed-dose combination product.

Long-term data, which involves tracking hard outcomes like major cardiovascular events, is not fully established specifically for Valax D over many years of use. Instead, evidence contributing to understanding long-term safety and cardiovascular risk reduction is largely derived indirectly from large-scale, extended-duration trials that utilized the valsartan component (one of the active ingredients) as part of broader treatment regimens in study populations identified by researchers as having certain cardiovascular risk factors.


Research Gaps and Areas of Uncertainty

Several limitations have been noted in the existing research landscape:

  • Long-term effects are not fully established for the specific Valax D fixed combination, as the majority of trials were focused on short-term blood pressure control.
  • Data for certain groups remain insufficient, particularly for high-risk patients outside the inclusion criteria of the original RCTs.
  • Comparative evidence is lacking to definitively assess the long-term clinical benefits of this specific combination over other dual therapy options for persistent hypertension.

Key Studies & References

  1. Valsartan/Hydrochlorothiazide: A review of its use in the management of hypertension (Review article on efficacy and tolerability)

Frequently Asked Questions (FAQ)

Common questions about Valax D (FAQ)

Q: Is it normal to feel a certain symptom (e.g., mild headache, nausea) when starting Valax D?

A: Official documents list headache as a common side effect and nausea as an uncommon side effect for this medicine. Side effects are typically reported based on their observed frequency in clinical studies. Experiencing a documented side effect when beginning treatment is consistent with clinical observation, and any new symptom can be discussed with a healthcare provider.

Q: Do side effects from Valax D usually go away as the body adjusts?

A: Information derived from clinical trial data indicates that adverse experiences associated with the medicine have generally been described as mild and transient (temporary) in nature. However, regulatory documents do not guarantee that any specific side effect will go away for every person as their body adjusts.

Q: What is the difference between an allergic reaction and a common side effect of Valax D?

A: Allergic reactions, such as the serious swelling of the face, lips, or tongue (angioedema), are listed as specific warnings or contraindications in official documents. Common side effects, like dizziness, are generally defined by their higher frequency of occurrence observed in clinical trials.

Q: Can Valax D interact with dietary supplements like multivitamins or herbal products?

A: Official product information specifies that certain supplements, such as potassium-sparing diuretics or bile acid sequestrants, have known interactions with the medicine. Patient guidance documents indicate that full disclosure of all prescription and over-the-counter medicines, vitamins, and herbal products taken is necessary for clinical assessment, as many of these may affect the drug.

Q: If Valax D doesn't seem to be working, what is the next typical step in treatment described in research?

A: Regulatory guidelines indicate that if blood pressure remains uncontrolled after a specific initial period (1 to 2 weeks of therapy), the dosage may be increased up to the maximum recommended daily dose. This process of adjusting the amount of medicine based on response is known as titration.

Q: What activities are generally advised to be avoided while taking Valax D due to its known effects?

A: Due to the risk of experiencing dizziness, lightheadedness, or fainting, official regulatory information notes that caution should be exercised when driving or operating machinery. This stated precaution is necessary until a person has a clear understanding of how the medicine affects their body and level of alertness.

Q: Why does Valax D come in different strengths or formulations?

A: The medicine is supplied in different strengths to allow for dose titration, which means adjusting the amount based on an individual’s blood pressure response. This flexibility helps in achieving the maximum blood pressure-lowering effect possible within the regulatory limits.

Q: Are there common patient misconceptions about how Valax D works that need clarification?

A: Official patient guidance often clarifies that Valax D is used to control high blood pressure, but it is not a cure for the condition. Since hypertension is typically a chronic issue, treatment with this medicine is often part of a long-term management plan.

Q: What information is available regarding Valax D and weight changes?

A: While weight change is not listed as a common side effect for the combination medicine, the hydrochlorothiazide component is classified as a diuretic, or 'water pill.' Fluid loss caused by a diuretic can be associated with fluctuations in body weight.

Q: Is Valax D prescribed for any condition outside of its main intended use?

A: The official regulatory indication for this fixed-dose combination product is strictly defined as the treatment of hypertension (high blood pressure). Regulatory indications define the intended medical use based on clinical evidence and official review.

Q: Can taking Valax D cause emotional changes or mood shifts?

A: Regulatory documents list adverse reactions by system organ class, including psychiatric disorders. Rare effects listed in official information include reports of anxiety, but this is not considered a common occurrence.

Q: Does Valax D require regular blood tests or monitoring while taking it?

A: Regulatory warnings state that patients should be monitored for signs of fluid or electrolyte imbalance. This typically involves monitoring renal function (kidney health) and potassium levels due to the risk of imbalance caused by the medicine’s components.

Q: Is there a maximum amount of time someone is generally expected to take Valax D for?

A: Regulatory guidance indicates that the medicine is used for the long-term control of high blood pressure. Because hypertension is typically a chronic condition, patients may need to take the medicine for an extended period.

Q: What if I have an existing heart condition? Is Valax D safe for people with certain pre-existing conditions?

A: Regulatory warnings advise caution in some patient populations, such as those with severe congestive heart failure. Official documents note that use in these specific groups may lead to potential kidney problems. Safety information regarding the use of this medicine alongside other heart conditions is not universally detailed and is subject to clinical review.

Q: What should be done if I experience a stomach upset after taking Valax D?

A: Abdominal pain or discomfort is listed as an uncommon side effect in regulatory documents. If severe gastrointestinal symptoms occur, such as vomiting or diarrhea, official guidance notes that a healthcare provider’s input is appropriate in cases of severe symptoms, as excessive fluid loss can lead to low blood pressure or electrolyte imbalance.

Q: Can Valax D affect sleep patterns or cause insomnia?

A: Regulatory documents group reported side effects into system-organ classes, including psychiatric effects. However, for this specific combination product, insomnia itself is not listed as a common or uncommon adverse reaction.

Q: Does taking Valax D require any major lifestyle changes, such as diet or exercise adjustments?

A: Regulatory patient information indicates that treatment for high blood pressure often involves broader lifestyle changes. These changes may include weight control and adjustments to the types of foods consumed, particularly those high in sodium. These changes are generally recommended as part of overall hypertension management.

Q: What should I be checking for to know if Valax D is having its intended effect?

A: The intended effect of the medicine is the reduction of high blood pressure. While the full benefit may take up to four weeks, blood pressure measurements are the primary way a healthcare provider checks for the effectiveness of the treatment.

How should Valax D be stored and disposed of?

How to Store and Dispose of Valax D?

The official storage and disposal guidelines for Valax D (Valsartan/Hydrochlorothiazide) are defined by regulatory agencies to ensure the medicine's stability and public safety.


Official Storage Conditions

Requirement Specifics Based on Regulatory Labeling
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the tablets protected from moisture, heat, and light.
Container Rule Store Valax D in its original, tightly closed, light-resistant container.
Prohibited Do not store the medicine in a bathroom or similar high-humidity location, and do not freeze the tablets.
Child Safety Keep Valax D out of the sight and reach of children.

Disposal Instructions

When disposing of unused or expired Valax D, regulatory guidance instructs that the medicine should not be discarded into household trash or poured into wastewater (sinks or toilets). The required method is to utilize official drug take-back programs or consult a pharmacist for approved disposal options that align with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valax D found in:

A-Z Index: